# "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"

> **NCT02058173** · PHASE4 · COMPLETED · sponsor: **Shiraz University of Medical Sciences** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** 150 mg/daily chloroquine compare to placebo for 12 week
- **DRUG:** Chloroquine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02058173
- **Lead sponsor:** Shiraz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058173, ""Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02058173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*